Targeting histone modifications - epigenetics in cancer

Current Opinion in Cell Biology

Volumn 25, Issue 2, 2013, Pages 184-189

  Waldmann, Tanja ^a   Schneider, Robert ^b,c  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; CLINICAL TRIAL (TOPIC); DNA METHYLATION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; TRANSCRIPTION ELONGATION; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; CHEMISTRY; CHROMATIN; DRUG EFFECT; EPIGENETICS; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONES; HUMANS; MUTATION; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

MLCS; MLOWN;

EID: 84877930649     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.01.001     Document Type: Review

References (47)

1. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
2. Fullgrabe J, Kavanagh E, Joseph B: Histone oncomodifications. Oncogene 2011, 30:3391-3403.
3. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A ° resolution. Nature 1997, 389:251-260.
4. Bannister AJ, Kouzarides T: Regulation of chromatin by histone modifications. Cell Res 2011, 21:381-395.
5. Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
6. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391-400.
7. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA et al.: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009, 69:3802-3809.
8. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA: Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007, 25:4358-4364.
9. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009, 174:1619-1628.
10. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC et al.: Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.
11. Kurdistani SK: Histone modifications in cancer biology and prognosis. Prog Drug Res 2011, 67:91-106.
12. Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, Muller SC, Ellinger J: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 2011, 108:E290-E296.
13. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
14. Behbahani TE, Kahl P, von der Gathen J, Heukamp LC, Baumann C, Gutgemann I, Walter B, Hofstadter F, Bastian PJ, von Ruecker A et al.: Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol 2012, 12:5.
15. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
16. Greer EL, Shi Y: Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012, 13:343-357.
17. Johnsen SA: The enigmatic role of H2Bub1 in cancer. FEBS Lett 2012, 586:1592-1601.
18. Ryan RJ, Bernstein BE: Molecular biology. Genetic events that shape the cancer epigenome. Science 2012, 336:1513-1514.
19. Stratmann A, Haendler B: Histone demethylation and steroid receptor function in cancer. Mol Cell Endocrinol 2012, 348:12-20.
20. You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
21. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N et al.: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
22. Li JY, Patterson M, Mikkola HK, Lowry WE, Kurdistani SK: Dynamic distribution of linker histone h1.5 in cellular differentiation. PLoS Genet 2012, 8:e1002879.
23. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al.: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
24. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M et al.: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012, 44:251-253.
25. Smeester L, Rager JE, Bailey KA, Guan X, Smith N, Garcia-Vargas G, Del Razo LM, Drobna Z, Kelkar H, Styblo M et al.: Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol 2011, 24:165-167.
26. Yoshida T, Yamauchi H, Fan Sun G: Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 2004, 198:243-252.
27. Thompson DJ: A chemical hypothesis for arsenic methylation in mammals. Chem Biol Interact 1993, 88:14-89.
28. Zhou X, Sun H, Ellen TP, Chen H, Costa M: Arsenite alters global histone H3 methylation. Carcinogenesis 2008, 29:1831-1836.
29. Chu F, Ren X, Chasse A, Hickman T, Zhang L, Yuh J, Smith MT, Burlingame AL: Quantitative mass spectrometry reveals the epigenome as a target of arsenic. Chem Biol Interact 2011, 192:113-117.
30. Ramirez T, Brocher J, Stopper H, Hock R: Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. Chromosoma 2008, 117:147-157.
31. Somji S, Garrett SH, Toni C, Zhou XD, Zheng Y, Ajjimaporn A, Sens MA, Sens DA: Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells. Cancer Cell Int 2011, 11:2.
32. Sutherland JE, Costa M: Epigenetics and the environment. Ann NY Acad Sci 2003, 983:151-160.
33. Cheng TF, Choudhuri S, Muldoon-Jacobs K: Epigenetic targets of some toxicologically relevant metals: a review of the literature. J Appl Toxicol 2012, 32:643-653.
34. Casati L, Sendra R, Colciago A, Negri-Cesi P, Berdasco M, Esteller M, Celotti F: Polychlorinated biphenyls affect histone modification pattern in early development of rats: a role for androgen receptor-dependent modulation?. Epigenomics 2012, 4:101-112.
35. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY et al.: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010, 70:7830-7840.
36. Chi P, Allis CD, Wang GG: Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469.
37. Vaiopoulos AG, Kostakis ID, Athanasoula K, Papavassiliou AG: Targeting transcription factor corepressors in tumor cells. Cell Mol Life Sci 2012, 69:1745-1753.
38. Ebbs ML, Bartee L, Bender J: H3 lysine 9 methylation is maintained on a transcribed inverted repeat by combined action of SUVH6 and SUVH4 methyltransferases. Mol Cell Biol 2005, 25:10507-10515.
39. Henckel A, Nakabayashi K, Sanz LA, Feil R, Hata K, Arnaud P: Histone methylation is mechanistically linked to DNA methylation at imprinting control regions in mammals. Hum Mol Genet 2009, 18:3375-3383.
40. Prendergast JG, Campbell H, Gilbert N, Dunlop MG, Bickmore WA, Semple CA: Chromatin structure and evolution in the human genome. BMC Evol Biol 2007, 7:72.
41. Schuster-Bockler B, Lehner B: Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012, 488:504-507.
42. Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R et al.: The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011, 25:673-678.
43. Riveiro-Falkenbach E, Soengas MS: Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010, 16:2932-2938.
44. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, Grosveld G: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992, 12:1687-1697.
45. Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C: Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004, 24:6011-6020.
46. Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Burkle A, Markovitz DM, Ferrando-May E: DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008, 28:3245-3257.
47. Tabbert A, Kappes F, Knippers R, Kellermann J, Lottspeich F, Ferrando-May E: Hypophosphorylation of the architectural chromatin protein DEK in death-receptor-induced apoptosis revealed by the isotope coded protein label proteomic platform. Proteomics 2006, 6:5758-5772.